Immunohistochemical Expression of ERα, ERβ, and TFF1 in Type I and II Ovarian Tumors

Abstract

Surface epithelial tumors of the ovary are no longer considered as a single disease but are divided into types I and II on the basis of their molecular features, cell of origin, and their behavior. A possible direct action of gonadal steroids on ovarian carcinogenesis has been suggested. The current information about the possible role of TFF1 in ovarian tumors,, together with its relationship to the estrogen receptor (ER) status, is insufficient. The aim of this study was to investigate ERα, ERβ, and TFF1 expression in type I and II ovarian tumors and their correlation with clinicopathologic parameters of each type. The present study was carried out on 97 ovarian tumors [20 benign, 15 borderline, and 62 malignant (36 type I and 26 type II tumors)]. ERα expression was significantly in favor of type II tumors (P=0.04), whereas high TFF1 expression was significantly in favor of type I tumors (P=0.02). ERα and ERβ showed a significant positive correlation in benign cases (P=0.004) and in type I tumors (P=0.006), but not in type II tumors. In type I tumors, the expression of ERα was correlated with serous carcinoma (P=0.002) and bilaterality (P=0.05), whereas TFF1 was correlated with mucinous carcinoma (P=0.02), unilaterality (P=0.04), early FIGO staging (P=0.01), and a low mitotic count (P=0.03). A high ERβ:ERα H score ratio was associated with advanced FIGO staging in both type I (P=0.05) and type II tumors (P=0.009). The difference in the expression of ERα and TFF1 between type I and II tumors may be indicative of the difference in their origin and molecular pathway. The ERβ:ERα ratio is more important in determining the net result of ER effects than the evaluation of each receptor separately, and the high ratio may promote progression to advanced stage in type I and II ovarian tumors. High TFF1 expression in ovarian mucinous carcinoma may indicate that their mucinous differentiation is toward an intestinal type rather than an endocervical type. TFF1 expression in ovarian tumors seems to occur independent of the status of the ER.

Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma

“…Many studies have concluded that the expression ratio between ER-α and ER-β determines the direction of response to oestrogens [27, 37, 38]. Thus, ER-α- and ER-β-selective agonists are promising new approach for treating specific conditions associated with endocrine-related disease [25].…”

“…Park et al ., (2008) [ 29 ] found that E2 triggered the metastatic behaviours exclusively through an ER-α-dependent pathway, but ER-β had an opposing action on ER-α in ovarian cancer. Many studies have concluded that the expression ratio between ER-α and ER-β determines the direction of response to oestrogens [ 27 , 37 , 38 ]. Thus, ER-α- and ER-β-selective agonists are promising new approach for treating specific conditions associated with endocrine-related disease [ 25 ].…”